GNOM News and Press, Global X Genomics & Biotechnology ETF From 06/09/22

BBIO lost hugely after the December phase 3 flop. So, although its business model is very interesting, it is not de-risked. It does have a lot of cash. For further details see: BridgeBio Pharma: Yet To Be Proven Business Model

Today, we revisit Outlook Therapeutics for the first time since March 2021. The company recently temporarily withdrew its marketing application for its main asset, clouding the outlook on this small-cap name even further. Should shareholders bail out or hold tight onto the stock? ...

Results from the phase 2a INTEGRIS-PSC study using PLN-74809 for the treatment of patients with primary sclerosing cholangitis are expected 1st half of 2023. PLN-74809 is also being explored for the treatment of patients with idiopathic pulmonary fibrosis; Preliminary safety and effic...

Directly or indirectly, peroxynitrite is responsible for much of the damage done to the brain in Alzheimer's disease. As a sigma-1 agonist, blarcamesine limits peroxynitrite formation by inhibiting intracellular calcium release. Blarcamesine likely scavenges peroxynitrite.  I...

As the recent Rett syndrome controversy shows, Anavex is a perpetually beleaguered stock. Despite the tremendous bearish headwind it always faces, the company has been able to increase shareholder value over the years. However, AVXL is still a highly risky, high blood pressure sto...

An Emergency Use Authorization submission of sabizabulin for high-risk hospitalized Covid-19 patients is expected Q2 of 2022. With EUA and then possibly NDA occurring for sabizabulin, Veru would be in a good position to develop advance purchase orders with several Government agencies ...

Positive results were announced from the phase 2 NCI-led PDS0101 triple-combination study in patients with HPV16+ cancers; both CPI naive and CPI refractory patients were helped. Positive results were also announced from the phase 2 study using PDS0101 + Keytruda for recurrent or meta...

Mirum's maralixibat was approved in September. The company looks like it is executing very well. I am waiting for dips to buy back in. For further details see: Mirum Pharmaceuticals: Post-Approval Execution Looks Excellent

Today, we put Twist Bioscience in the spotlight for the first time. The stock has lost approximately two-thirds of its market value in 2022 despite posting better than expected quarterly results earlier this month. A full investment analysis follows in the paragraphs below. ...

Harmony has done very well monetizing their first asset. They have to start planning for the future. Expanding Wakix labels and acquiring new, late stage assets, are key steps. For further details see: Harmony Biosciences: Steady Revenue Generator Looking For A Future